Doretta Cuffaro

Dr. Doretta Cuffaro

Department of Pharmacy, University of Pisa, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MCMatteo Calligaris
Matteo Calligaris
DCDoretta Cuffaro
Doretta Cuffaro
SBSimone Bonelli
Simone Bonelli
DSDonatella Pia Spanò
Donatella Pia Spanò
ARArmando Rossello
Armando Rossello
Simone D. ScilabraSimone D. Scilabra
Simone D. Scilabra
For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions. Furthermore, here, we comprehensively encompass the approaches that have been developed to accomplish ADAM17 selective inhibition, from the newest non-zinc-binding ADAM17 synthetic inhibitors to the exploitation of iRhom2 to specifically target ADAM17 in immune cells.

4 May 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Elisa NutiElisa Nuti
Elisa Nuti
DCDoretta Cuffaro
Doretta Cuffaro
EBElisa Bernardini
Elisa Bernardini
CCCaterina Camodeca
Caterina Camodeca
LPLaura Panelli
Laura Panelli
ARArmando Rossello
Armando Rossello

26 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
DCDoretta Cuffaro
Doretta Cuffaro
Andrea BertoliniAndrea Bertolini
Andrea Bertolini
SBSimone Bertini
Simone Bertini
CRClaudio Ricci
Claudio Ricci
MCMaria Grazia Cascone
Maria Grazia Cascone
MDMARIA DIGIACOMO
MARIA DIGIACOMO
Background: Agrifood waste products are often considered rich sources of bioactive compounds that can be conveniently recovered. Due to these peculiar characteristics, the study of these waste products is attracting great interest in nutraceutical research. Olive mill wastewaters (OMWWs) are generated by extra virgin olive oil (EVOO) production, and they pose environmental challenges due to their disposal. This study aimed to characterize the polyphenolic profile and to evaluate the nutraceutical properties of OMWW extracts from two Tuscan olive cultivars, Leccino (CL) and Frantoio (CF), collected during different time points in EVOO production. Method: After a liquid–liquid extraction, the HPLC and LC–MS/MS analysis of OMWW extracts confirmed the presence of 18 polyphenolic compounds. Results: The polyphenol composition varied between the cultivars and during maturation stages. Notably, oleacein was detected at remarkably high levels in CL1 and CF1 extracts (314.628 ± 19.535 and 227.273 ± 3.974 μg/mg, respectively). All samples demonstrated scavenging effects on free radicals (DPPH and ABTS assays) and an anti-inflammatory potential by inhibiting cyclooxygenase (COX) enzymes. Conclusions: This study highlights the nutraceutical potential of OMWW extracts, emphasizing their antioxidant, antiradical, and anti-inflammatory activities. The results demonstrate the influence of olive cultivar, maturation stage, and extraction process on the polyphenolic composition and the bioactivity of OMWW extracts. These findings support a more profitable reuse of OMWW as an innovative, renewable, and low-cost source of dietary polyphenols with potential applications as functional ingredients in the development of dietary supplements, as well as in the pharmaceutical and cosmetics industries.

30 June 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
Elisa NutiElisa Nuti
Elisa Nuti
DCDoretta Cuffaro
Doretta Cuffaro
FDFelicia D'Andrea
Felicia D'Andrea
LRLea Rosalia
Lea Rosalia
LTLivia Tepshi
Livia Tepshi
ARArmando Rossello
Armando Rossello

1 January 2020 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
DCDoretta Cuffaro
Doretta Cuffaro
Elisa NutiElisa Nuti
Elisa Nuti
ARArmando Rossello
Armando Rossello
Carbonic anhydrases (CAs) are metalloenzymes responsible for the reversible hydration of carbon dioxide to bicarbonate, a fundamental reaction involved in various physiological and pathological processes. In the last decades, CAs have been considered as important drug targets for different pathologies such as glaucoma, epilepsy and cancer. The design of potent and selective inhibitors has been an outstanding goal leading to the discovery of new drugs. Among the different strategies developed to date, the design of carbohydrate-based CA inhibitors (CAIs) has emerged as a versatile tool in order to selectively target CAs. The insertion of a glycosyl moiety as a hydrophilic tail in sulfonamide, sulfenamide, sulfamate or coumarin scaffolds allowed the discovery of many different series of sugar-based CAIs, with relevant inhibitory results. This review will focus on carbohydrate-based CAIs developed so far, classifying them in glycosidic and glycoconjugated inhibitors based on the conjugation chemistry adopted.

5 May 2020 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
ASAnke Seifert
Anke Seifert
SDStefan Düsterhöft
Stefan Düsterhöft
JWJustyna Wozniak
Justyna Wozniak
CKConnie Koo
Connie Koo
MTMichael G. Tomlinson
Michael G. Tomlinson
ALAndreas Ludwig
Andreas Ludwig
The metalloproteinase ADAM10 critically contributes to development, inflammation, and cancer and can be controlled by endogenous or synthetic inhibitors. Here, we demonstrate for the first time that loss of proteolytic activity of ADAM10 by either inhibition or loss of function mutations induces removal of the protease from the cell surface and the whole cell. This process is temperature dependent, restricted to mature ADAM10, and associated with an increased internalization, lysosomal degradation, and release of mature ADAM10 in extracellular vesicles. Recovery from this depletion requires de novo synthesis. Functionally, this is reflected by loss and recovery of ADAM10 substrate shedding. Finally, ADAM10 inhibition in mice reduces systemic ADAM10 levels in different tissues. Thus, ADAM10 activity is critically required for its surface expression in vitro and in vivo. These findings are crucial for development of therapeutic ADAM10 inhibition strategies and may showcase a novel, physiologically relevant mechanism of protease removal due to activity loss.